8-K: Grace Therapeutics Files GTx-104 NDA, Reports Q1 Loss

Grace Therapeutics submitted a New Drug Application for GTx-104 to the FDA for aSAH treatment, reporting a net loss of $3.4 million for the quarter ended June 30, 2025.

Summary

• Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for GTx-104, seeking approval for the treatment of patients with aneurysmal Subarachnoid Hemorrhage (aSAH).
• The NDA is supported by data from the Phase 3 STRIVE-ON safety trial, which met its primary endpoint and provided evidence of clinical benefit compared to orally administered nimodipine.
• Reported a net loss of $3.4 million, or $0.21 per share, for the three months ended June 30, 2025 (First Quarter 2026), an increase of $0.8 million from the $2.6 million net loss in the prior year period.
• The increase in net loss was primarily due to a $1.9 million difference in the change in fair value of derivative warrant liabilities and a $0.7 million decrease in income tax benefit.
• Total research and development expenses decreased by approximately $1.8 million to $0.9 million for the quarter, mainly due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial.
• General and administrative expenses decreased by $0.1 million to $2.1 million for the quarter.
• Cash and cash equivalents were $20.0 million as of June 30, 2025, a net decrease of approximately $2.1 million from March 31, 2025.
• The company holds Orphan Drug Designation from the FDA for GTx-104, which generally provides seven years of marketing exclusivity upon approval.
• Development of GTx-102 and GTx-101 has been deprioritized to focus on GTx-104, with potential for licensing or sale of these assets.

Sentiment

Score: 7

Explanation: The submission of the NDA for the lead candidate GTx-104, supported by positive Phase 3 data, is a major positive milestone for a biopharma company, significantly de-risking the primary asset. While the net loss increased, it's largely due to non-cash items and reduced R&D post-trial, which is expected. The cash runway is adequate, with significant potential capital from warrants. The deprioritization of other assets focuses resources but also indicates a narrower pipeline. The overall sentiment is positive due to the advancement of the lead asset towards commercialization.

Positives

• Submitted a New Drug Application (NDA) for GTx-104 to the FDA, a significant milestone for the company.
• The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine (28% vs 35%).
• GTx-104 showed improved clinical outcomes, with 54% of patients achieving 95% or higher relative dose intensity (RDI) compared to only 8% on oral nimodipine.
• GTx-104 led to 29% more patients having favorable functional outcomes at 90 days compared to oral nimodipine.
• Patients receiving GTx-104 experienced fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days.
• GTx-104 has Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity in the United States upon approval.
• The company believes its U.S. and international patent estate will provide additional marketing exclusivity for GTx-104.
• Research and development expenses significantly decreased by $1.8 million due to the completion of the pivotal Phase 3 STRIVE-ON trial.
• Potential for $22.6 million in gross proceeds from the exercise of existing warrants, which could extend the cash runway.

Negatives

• Net loss increased to $3.4 million for the quarter ended June 30, 2025, compared to $2.6 million for the same period in the prior year.
• The increase in net loss was primarily driven by a $1.9 million difference in the change in fair value of derivative warrant liabilities and a $0.7 million decrease in income tax benefit.
• Cash and cash equivalents decreased by $2.1 million during the quarter, from $22.1 million to $20.0 million.
• Development of GTx-102 and GTx-101 has been deprioritized, indicating a narrower pipeline focus and potential divestment of these assets.
• In the STRIVE-ON trial, there were 8 deaths on the GTx-104 arm compared to 4 deaths on the oral nimodipine arm, although all deaths were attributed to the severity of the patients' underlying disease and not the drug.

Risks

• The success and timing of regulatory submissions and the ultimate outcome of the FDA's NDA application for GTx-104 are uncertain.
• Regulatory requirements or developments and potential changes to regulatory pathways could impact the approval process.
• Legislative, regulatory, political, and economic developments could affect the company's operations and financial performance.
• The company's cash runway beyond the next twelve months is dependent on the exercise of warrants, which is at the election of investors.
• The FDA has a 60-day period to determine if the NDA is complete and acceptable for filing, and acceptance is not guaranteed.

Future Outlook

The company is hopeful the FDA will accept the NDA for GTx-104 for formal review and looks forward to continued engagement with the FDA during the review process. Management believes current cash and cash equivalents provide a cash runway through at least the next twelve months, with the potential to extend into the second quarter of calendar 2027 if all common warrants issued in connection with the February 2025 and September 2023 private placements are exercised.

Management Comments

• "During our first quarter of 2026 we continued to execute on our clinical and corporate goals, led by the submission of our NDA to the FDA for GTx-104 for the treatment of aSAH."
• "Our NDA for GTx-104 was a significant milestone for the Company and built on more than a decade of painstaking research and innovation."
• "The standard of care for aSAH has not seen meaningful innovation in nearly 40 years, and we believe the STRIVE-ON trial results point to a very promising role for GTx-104 as a potential breakthrough for the care of aSAH patients."
• "We are hopeful the FDA will accept our NDA for formal review, and look forward to continued engagement with the FDA during the review process."

Industry Context

Aneurysmal Subarachnoid Hemorrhage (aSAH) is a rare but severe type of stroke, accounting for about 5% of all strokes and affecting an estimated 42,500 U.S. hospital-treated patients. The industry has seen little innovation in aSAH treatment for nearly 40 years, indicating a significant unmet medical need. Grace Therapeutics' focus on GTx-104, an injectable formulation of nimodipine, aligns with the biopharma trend of developing improved drug delivery methods and targeting orphan diseases, which often benefit from expedited regulatory pathways and market exclusivity.

Comparison to Industry Standards

• GTx-104 is positioned as an improvement over the current standard of care, orally administered nimodipine, for aSAH patients.
• The Phase 3 STRIVE-ON trial demonstrated a 19% reduction in clinically significant hypotension for GTx-104 (28%) compared to oral nimodipine (35%).
• GTx-104 achieved a significantly higher relative dose intensity (RDI) of 95% or higher in 54% of patients, versus only 8% for oral nimodipine, indicating better drug exposure.
• GTx-104 resulted in 29% more patients having favorable functional outcomes at 90 days compared to oral nimodipine.
• Patients receiving GTx-104 experienced fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days, suggesting potential medical and pharmacoeconomic benefits over oral nimodipine.
• The unique nanoparticle technology of GTx-104 facilitates aqueous formulation for standard peripheral IV infusion, potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients, a common issue with oral nimodipine.
• Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors, which are advantages over oral formulations.

Stakeholder Impact

• Shareholders: Potential for significant value creation if GTx-104 receives FDA approval and is successfully commercialized; potential dilution from warrant exercises; increased net loss impacts short-term profitability.
• Patients (aSAH): Potential for a new, improved treatment option for a life-threatening condition with significant unmet medical needs.
• Employees: Continued focus on the development and potential commercialization of GTx-104.

Next Steps

• FDA's 60-day period to determine if the NDA for GTx-104 is complete and acceptable for filing.
• Continued engagement with the FDA during the review process for GTx-104.
• Potential exercise of September 2023 warrants upon FDA acceptance of the GTx-104 NDA.
• Potential exercise of February 2025 warrants upon FDA approval of the GTx-104 NDA.
• Potential licensing or sale of deprioritized assets GTx-102 and GTx-101.

Key Dates

Recommendation

The NDA submission for GTx-104 is a significant positive catalyst, backed by strong Phase 3 data, and addresses a critical unmet medical need with orphan drug designation. This de-risks the primary asset considerably. However, the financial results show an increased net loss, and while R&D decreased, the company is still burning cash. The cash runway is sufficient for the near term, but future funding relies on warrant exercises, which are at the investors' discretion. The deprioritization of other pipeline assets narrows the company's future growth avenues beyond GTx-104. Given the major milestone achieved, the stock may see an initial positive reaction, but the next major catalyst is FDA acceptance and then approval, which introduces regulatory uncertainty. For a seasoned investor, holding to observe the FDA's review process and the company's commercialization strategy for GTx-104, while monitoring cash burn and potential warrant exercises, would be prudent.

Keywords

Grace Therapeutics, GTx-104, aSAH, aneurysmal Subarachnoid Hemorrhage, FDA, NDA, biopharma, clinical trial, STRIVE-ON, nimodipine, orphan drug, Q1 2026 financial results, cash runway, GRCE